PT1007686E - Vacina contra a tuberculose - Google Patents

Vacina contra a tuberculose Download PDF

Info

Publication number
PT1007686E
PT1007686E PT98947427T PT98947427T PT1007686E PT 1007686 E PT1007686 E PT 1007686E PT 98947427 T PT98947427 T PT 98947427T PT 98947427 T PT98947427 T PT 98947427T PT 1007686 E PT1007686 E PT 1007686E
Authority
PT
Portugal
Prior art keywords
nucleic acid
domain
cell
acid molecule
polypeptide
Prior art date
Application number
PT98947427T
Other languages
English (en)
Portuguese (pt)
Inventor
Stefan H E Kaufmann
Juergen Hess
Original Assignee
Max Planck Ges Zur Forderung W
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Ges Zur Forderung W filed Critical Max Planck Ges Zur Forderung W
Publication of PT1007686E publication Critical patent/PT1007686E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PT98947427T 1997-08-22 1998-08-12 Vacina contra a tuberculose PT1007686E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97114614A EP0902086A1 (en) 1997-08-22 1997-08-22 Tuberculosis vaccine

Publications (1)

Publication Number Publication Date
PT1007686E true PT1007686E (pt) 2007-03-30

Family

ID=8227261

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98947427T PT1007686E (pt) 1997-08-22 1998-08-12 Vacina contra a tuberculose

Country Status (13)

Country Link
US (1) US6673353B1 (enExample)
EP (2) EP0902086A1 (enExample)
JP (1) JP4255209B2 (enExample)
AT (1) ATE347599T1 (enExample)
AU (1) AU9435098A (enExample)
CA (1) CA2301879C (enExample)
CY (1) CY1106350T1 (enExample)
DE (1) DE69836588T2 (enExample)
DK (1) DK1007686T3 (enExample)
ES (1) ES2274580T3 (enExample)
PT (1) PT1007686E (enExample)
SI (1) SI1007686T1 (enExample)
WO (1) WO1999010496A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7794729B2 (en) 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US7662396B2 (en) 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
CA2348475A1 (en) * 1998-11-04 2000-05-11 Isis Innovation Limited Tuberculosis diagnostic test
GB0006693D0 (en) * 2000-03-20 2000-05-10 Glaxo Group Ltd Vaccine
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
IL151942A0 (en) 2000-03-29 2003-04-10 Univ Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
KR101192652B1 (ko) * 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
MXPA05011360A (es) 2003-04-23 2005-11-28 Max Planck Gesellschaft Vacuna contra la tuberculosis con eficiencia mejorada.
EP1649869A1 (en) * 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
AP2007004033A0 (en) * 2004-12-01 2007-06-30 Aeras Global Tb Baccine Founda Recombinant bcg strains with enhanced ability to escape the endosome
US8241636B2 (en) 2006-08-15 2012-08-14 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
WO2009143167A2 (en) 2008-05-19 2009-11-26 Advaxis Dual delivery system for heterologous antigens
EP3269799A1 (en) 2009-03-04 2018-01-17 The Trustees of the University of Pennsylvania Compositions comprising angiogenic factors and uses thereof
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
EP3360569B1 (en) * 2010-09-20 2020-03-18 Vakzine Projekt Management GmbH Recombinant mycobacterium as vaccine for use in humans
JP5981436B2 (ja) 2010-10-01 2016-08-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 寄生的に感染している対象におけるワクチン不応答性を反転させるためのリステリアワクチンベクターの使用
EP2654783B1 (en) 2010-12-21 2016-10-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant mycobacterium as a vaccine
SI2656070T1 (sl) * 2010-12-21 2016-05-31 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Ugotavljanje učinkovitosti živega rekombinantnega antimikobakterijskega cepljenja
WO2012125551A1 (en) 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
BR102012003790A2 (pt) 2012-02-17 2014-04-22 Fundacao Butantan Cepa de mycobacterium recombinante, composição imunogênica e uso
HK1205944A1 (en) 2012-03-12 2015-12-31 阿德瓦希斯公司 Suppressor cell function inhibition following listeria vaccine treatment
AU2013243922A1 (en) * 2012-04-02 2014-10-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium for induction of cellular immune response

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504005A (en) * 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine

Also Published As

Publication number Publication date
SI1007686T1 (sl) 2007-04-30
US6673353B1 (en) 2004-01-06
CY1106350T1 (el) 2011-10-12
ATE347599T1 (de) 2006-12-15
AU9435098A (en) 1999-03-16
DE69836588D1 (de) 2007-01-18
EP1007686B1 (en) 2006-12-06
EP1007686A1 (en) 2000-06-14
CA2301879C (en) 2014-02-04
JP2001514000A (ja) 2001-09-11
CA2301879A1 (en) 1999-03-04
EP0902086A1 (en) 1999-03-17
DE69836588T2 (de) 2007-04-05
DK1007686T3 (da) 2007-04-10
JP4255209B2 (ja) 2009-04-15
ES2274580T3 (es) 2007-05-16
WO1999010496A1 (en) 1999-03-04

Similar Documents

Publication Publication Date Title
PT1007686E (pt) Vacina contra a tuberculose
US8545854B2 (en) Tuberculosis vaccine with improved efficacy
US8043857B2 (en) Recombinant BCG strains with enhanced ability to escape the endosome
CN101273055A (zh) 用于预防或治疗结核分枝杆菌感染的新方法
US6776993B2 (en) Tuberculosis vaccine
AU2002222098A1 (en) Projection against mycobacterial infections
HK1091217B (en) Tuberculosis vaccine with improved efficacy
Rezwan Lipoprotein maturation is required for virulence of Mycobacterium tuberculosis and is essential for correct lipoprotein localization
MX2007006551A (en) Recombinant bcg strains with enhanced ability to escape the endosome